Home > Medical Writing
MEDICAL WRITING SERVICES
BioBoston CRO provides medical writing services for sponsors that need clear, reviewable clinical and regulatory documents supported by an organized authoring process. Engagements can address one defined document, a set of related deliverables, a temporary capacity gap, or an independent quality-control need.
The Medical Writing pillar owns category-level writing support. Exact document needs are routed to dedicated pages for Submission Writing, Clinical Study Report Writing, FDA Briefing Book Writing, Investigator Brochure Support, and Protocol Writing. Regulatory Affairs remains the owner of pathway, submission strategy, sequencing, and regulatory planning.
Global Reach
Therapeutic Area Coverage
Years of Experience
START A CONVERSATION
Select the support you need and share a few details about your project. We’ll use this information to route your inquiry to the appropriate BioBoston team member.
Please do not submit confidential, patient-identifiable, or proprietary information through this form.
SERVICES
Author or develop clinical and regulatory submission content, including appropriate Common Technical Document
or electronic Common Technical Document modules and supporting documents. Regulatory Affairs owns
submission strategy, sequencing, and application management.
Buyer relevance: Sponsors with defined submission plans that need document and module authoring capacity.
Develop a clear Clinical Study Report from the approved reporting strategy, study data, analyses, source
documents, and cross-functional input.
Buyer relevance: Sponsors approaching study reporting, disclosure, submission, or internal decision milestones.
Develop the meeting package and briefing-book content that presents the sponsor’s background, questions,
rationale, data, and proposed path clearly. Regulatory Affairs owns meeting and regulatory strategy.
Buyer relevance: Sponsors preparing for an FDA interaction with an approved meeting strategy and content plan
Author, update, or review the Investigator Brochure using the current nonclinical, clinical, safety, product, and
program information supplied by the sponsor.
Buyer relevance: Programs preparing an initial brochure, annual update, major revision, or consistency review.
Translate an approved study concept, synopsis, objectives, endpoints, and cross-functional inputs into a
complete, reviewable clinical protocol. Product Development Planning owns early protocol concept and synopsis
work.
Buyer relevance: Sponsors that have the study concept substantially defined and need full protocol authoring or draft
rescue.
The review scope should be defined in advance. Depending on the document and risk, it may include editorial accuracy, internal consistency, source verification, terminology, completeness, formatting, cross-document alignment, unresolved placeholders, comment disposition, and readiness for the next review or approval step.
Common Triggers
Practical outcomes
The purpose, audience, key messages, structure, and supporting evidence are easier for reviewers to understand.
Contributors know when and how to review, where decisions are recorded, and how comments are consolidated.
Definitions, study details, product information, data references, and strategic assumptions remain aligned across related materials.
The sponsor can see source dependencies, drafting stages, review cycles, approvals, and issues that may affect delivery.
The document receives appropriate editorial, technical, consistency, and completeness checks before finalization.
RELATED SERVICES
Use Regulatory Affairs for pathway, meeting strategy, submission planning, sequencing, regulatory positioning, and application-management decisions.
Use Product Development Planning for clinical development plans, early study concepts, protocol synopses, endpoint strategy, CRO selection, and early trial budget review.
Engage Biostatistics for sample size, estimands and analysis concepts where applicable, statistical analysis plans, randomization, tables, listings, figures, and programming.
Align electronic case report forms, data-management plans, database design, data standards, and lock-readiness decisions with what the clinical documents require.
Coordinate document schedules, dependencies, review cycles, vendor interfaces, responsibilities, and escalation when several deliverables must move together.
WHAT AN ENGAGEMENT MAY PRODUCE
HOW THE WORK IS MANAGED
Confirm the document’s intended use, audience, owner, reviewers, decision rights, and approval path before drafting accelerates.
Identify missing inputs, conflicting information, unresolved decisions, and dependencies that could create avoidable rewrite cycles.
Agree on the document logic, key messages, and content responsibilities before investing heavily in sentence level refinement.
Use a controlled review method that distinguishes required corrections, strategic decisions, preferences, and out of-scope requests.
The writer can integrate and explain input, but the sponsor and designated subject-matter owners remain responsible for decisions and approvals.
ENGAGEMENT PROCESS
1. Scope the document, audience, milestone, source package, review team, deliverables, and working model.
2. Review source materials and create an input-gap list, outline, authoring plan, and responsibility map.
3. Draft the document in agreed sections while tracking assumptions, questions, and dependencies.
4.. Coordinate a consolidated cross-functional review and resolve comments through the designated decision owners.
5. Perform the agreed quality-control checks and prepare clean, redline, and finalization versions.
6. Support sponsor approval, publishing handoff, or downstream document coordination as defined in scope.
Medical writing support is most useful when the document is important enough to require experienced judgment, disciplined review, and consistency across functions, but the sponsor does not have the right capacity available at the required time.
Add senior writing capacity without building a permanent internal medical writing function before the workload supports it.
Protect a submission, meeting, study-start, database-lock, or reporting milestone when internal writers and reviewers are already committed.
Create one controlled document from medical, statistical, regulatory, operational, quality, data, and product source material.
Restructure, complete, or stabilize a document that has stalled because the source package, ownership, or review process is unclear.
WRITER AND REVIEWER FIT
Medical writing experience is most useful when it matches the document type, product, development stage, intended audience, source complexity, and review environment. BioBoston should present the selected writer or reviewer through approved, specific experience rather than broad claims.
PLANNED GUIDANCE
A planned educational article covering writer selection, source readiness, review structure, document quality, and common sponsor decisions. .
A planned overview that explains common clinical and regulatory document categories and how they connect across development.
A planned buyer guide focused on writer fit, delivery model, review responsibilities, quality controls, and vendor evaluation.
FAQs
The approved CRO structure includes Submission Writing, Clinical Study Report Writing, FDA Briefing Book Writing, Investigator Brochure Support, and Protocol Writing. Medical Writing Quality Control may also be scoped as an additional capability. The exact document, product, stage, and delivery model should be confirmed during intake.
Yes, a rescue or completion engagement may begin with an existing draft. The first step is to assess the document structure, open decisions, source package, comment history, review ownership, and remaining milestone so the scope reflects the actual condition of the work.
Medical Writing owns document authoring, narrative development, review integration, and document quality.
Regulatory Affairs owns pathway, regulatory positioning, meeting strategy, submission sequencing, and
application planning. The two functions should coordinate, but the pages should not target the same primary
intent.
Yes. An independent review can be scoped for editorial quality, source verification, consistency,
completeness, technical content, cross-document alignment, or final readiness. The review criteria andreviewer qualifications should be agreed before work begins.
Useful inputs include the document type, intended use, current stage, target milestone, source documents, sponsor template, review team, known open issues, related documents, expected review cycles, and the desired authoring or quality-control role.
Timing depends on document complexity, source readiness, review availability, decision latency, number of review cycles, and whether the work begins from a concept, outline, partial draft, or mature source package. BioBoston should provide a schedule only after reviewing those inputs.
The engagement can be designed around sponsor-approved templates, style guides, review processes, and document-control requirements. Any specific platform or software capability should be confirmed during scoping rather than assumed on the public page.
PROJECT FORM
Share the document type, current stage, target milestone, and the type of writing or quality-control support you need. A BioBoston team member will review the request and follow up regarding fit and next steps.
Please do not submit confidential, patient-identifiable, or proprietary information through this form.
A productive first discussion starts with the document, its current condition, the target milestone, and the decisions that remain open. BioBoston can then determine the writer profile, authoring model, review process,
related service dependencies, and realistic next step.
